‹ ›
MYP_151357
← PREVIOUS NEXT → BACK
Basic Information
EBR28[Q2A]
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral replication inhibition
Enzyme modulation ▸ Enzyme inhibition ▸ Integrase inhibition
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
12 amino acids
C72H119N17O16S
Standard
Sequence
YALLIRMIYKNI
Physicochemical Analysis
1510.88 Da
9.70
1.76
1.55
0.1464
0.86
0.56
0.27
65.52
170.83
0.1667
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
554.89
-0.10
20.0
19.0
50.0
106.0
2.0
12.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0073555 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
inhibition of HIV-1 infection in HeLa CD4-β-Gal cells
IC50
PaperA novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase PMID12054767 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12054767/
RECORD: Rec_0084113 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Replication inhibition
HIV-1 | -Gal cells
100 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperA novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. | de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. | J Mol Biol. 2002 Apr 19;318(1):45-58. | DOI:10.1016/S0022-2836(02)00033-5 | PMID:12054767 PMID12054767 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12054767/
RECORD: Rec_0118797 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral Cytotoxic
PaperA novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase PMID12054767 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12054767/
RECORD: Rec_0158091 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Integrase inhibition
HeLa
8 μM
IC50
PaperA novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. PMID12054767 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12054767/
RECORD: Rec_0160016 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Replication inhibition
HIV-1
8 μM
IC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperA novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. | de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. | J Mol Biol. 2002 Apr 19;318(1):45-58. | DOI:10.1016/S0022-2836(02)00033-5 | PMID:12054767 PMID12054767 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12054767/
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2